Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2013

View Archived Issues

Novartis presents highlights of fourth quarter 2012

Promising efficacy reported for veliparib in pancreatic cancer

ASG-5ME evaluated in patients with pancreatic ductal adenocarcinoma

New homoerythromycins reported by Luoyang Huizhong Animal Medicine

Amakem discloses novel protein kinase C inhibitors

Mochida Pharmaceutical discloses new PDE10A inhibitors

H. Lundbeck patents novel nAChR positive allosteric modulators

Novel orexin receptor antagonists presented by Taisho Pharmaceutical

Nanjing Sanhome Pharmaceutical synthesizes new tubulin polymerization inhibitors

New agents for HIV infection presented by Gilead Sciences

4CMenB demonstrates promising immunogenicity in phase III trials

Antisense Therapeutics begins phase II trial of ATL-1103

Antitope forms protein deimmunization agreement

SymBio completes phase II trial of antiemetic transdermal patch

FDA approves three alogliptin-based therapies for type 2 diabetes

Phase III trial compares linifanib and sorafenib in hepatocellular carcinoma

Threshold Pharmaceuticals begins phase III MAESTRO study in pancreatic cancer

Pharmstandard and Janssen Pharmaceutica collaborate on TB drugs

Seattle Genetics and Millennium begin phase III trial of Adcetris

Genzyme's sBLA for Lemtrada in relapsing MS accepted for review

FDA approves Prevnar 13 pneumococcal vaccine for older children and adolescents

Findings from phase II/III study of Anyara in renal cell carcinoma presented

PD-0332991 is well tolerated in patients with recurrent or refractory advanced HCC

FDA approves Gleevec for children with Ph+ ALL

OncoTherapy Science expands gastric cancer study of OTSGC-A24

Digna Biotech initiates phase I trial of gene therapy product for acute intermittent porphyria

Baxter to acquire hemophilia compound OBI-1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...